Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis. Front Public Health. 2022;26(10): 873596.

Article  Google Scholar 

Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–20.

Article  PubMed  Google Scholar 

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.

Article  CAS  PubMed  Google Scholar 

Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790–8.

Article  CAS  PubMed  Google Scholar 

Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84.

Article  PubMed  Google Scholar 

Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data. Viruses. 2023. https://doi.org/10.3390/v15040976.

Article  PubMed  PubMed Central  Google Scholar 

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–9.

Article  CAS  PubMed  Google Scholar 

Ganatra S, Dani SS, Ahmad J, Kumar A, Shah J, Abraham GM, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563–72.

Article  CAS  PubMed  Google Scholar 

Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022. Am J Transplant. 2023;23(1):150–5.

Article  PubMed  PubMed Central  Google Scholar 

Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023. https://doi.org/10.1016/S1473-3099(23)00011-7.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz KL, Wang J, Tadrous M, Langford BJ, Daneman N, Leung V, et al. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19. CMAJ. 2023;195(6):E220–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281–93.

Article  CAS  PubMed  Google Scholar 

Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, et al. Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open. 2023;13(8): e069176.

Article  PubMed  PubMed Central  Google Scholar 

Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2023. https://doi.org/10.1016/S1473-3099(23)00493-0.

Article  PubMed  PubMed Central  Google Scholar 

Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;7(380): e072705.

Article  Google Scholar 

Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study. J Infect. 2023;86(4):352–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin DY, Abi Fadel F, Huang S, Milinovich AT, Sacha GL, Bartley P, et al. Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections. JAMA Netw Open. 2023;6(9): e2335077.

Article  PubMed  PubMed Central  Google Scholar 

Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida Ν, Gkolfinopoulou K, et al. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients. J Infect Dis. 2023. https://doi.org/10.1093/infdis/jiad324.

Article  PubMed  PubMed Central  Google Scholar 

Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;25(381): e074572.

Article  Google Scholar 

Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023. https://doi.org/10.1001/jamainternmed.2023.0743.

Article  PubMed  PubMed Central  Google Scholar 

How Test to Treat Works for Individuals and Families. Available from: https://aspr.hhs.gov/TestToTreat/Pages/process.aspx

Smith ER, Oakley EM. Geospatial disparities in federal COVID-19 test-to-treat program. Am J Prev Med. 2023;64(5):761–4.

Article  PubMed  PubMed Central  Google Scholar 

Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations

Parkinson J. ContagionLive. 2023. FDA No Longer Requires Positive COVID-19 Test to Use 2 Antivirals. Available from: https://www.contagionlive.com/view/fda-no-longer-requires-positive-covid-19-test-to-use-2-antivirals

Levy ME, Burrows E, Chilunda V, Pawloski PA, Heaton PR, Grzymski J, et al. SARS-CoV-2 antiviral prescribing gaps among non-hospitalized high-risk adults. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciad796.

Article  PubMed  Google Scholar 

Ma KC, Shirk P, Lambrou AS, Hassell N, Zheng XY, Payne AB, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages—United States, January 2022–May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(24):651–6.

Article  PubMed  PubMed Central  Google Scholar 

Ipsos. Be Sure with KnowledgePanel®. 2018. Available from: https://www.ipsos.com/sites/default/files/18-11-53_Overview_v3.pdf

US Census Bureau. Current Population Survey Datasets [Internet]. [cited 2023 Jun 1]. Available from: https://www.census.gov/programs-surveys/cps/data/datasets.html

US Census Bureau. Data Releases. Available from: https://www.census.gov/programs-surveys/acs/news/data-releases.2021.html#list-tab-1133175109

Bradley VC, Kuriwaki S, Isakov M, Sejdinovic D, Meng XL, Flaxman S. Unrepresentative big surveys significantly overestimated US vaccine uptake. Nature. 2021;600(7890):695–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

CDC. Centers for Disease Control and Prevention. 2023 [cited 2023 Jun 1]. People with Certain Medical Conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones HE, McNairy M, et al. The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022. Prev Med. 2023;169: 107461.

Article  PubMed  PubMed Central